Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 1/20 | 0.60 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.60 |
| ▸ | ERN1 | O75460 | 17/20 | 0.59 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7166417 | 0.92 | MCL1 (0.52) | MCL1ACMSDERN1TLR8CA12 | |
| SCHEMBL31017149 | 0.88 | ERN1 (0.53) | MCL1ACMSDERN1TLR8 | |
| SCHEMBL5340123 | 0.88 | MCL1 (0.56) | MCL1ACMSDERN1TLR8CA12 | |
| SCHEMBL12989293 | 0.84 | ERN1 (0.53) | ERN1 | |
| SCHEMBL16058511 | 0.82 | ERN1 (0.51) | MCL1ACMSDERN1 | |
| SCHEMBL30462312 | 0.80 | ERN1 (0.55) | ERN1 | |
| SCHEMBL3972531 | 0.80 | ERN1 (0.53) | MCL1ACMSDERN1 | |
| SCHEMBL28350260 | 0.80 | APP (0.67) | MCL1ACMSDTLR8CA12CA1 | |
| SCHEMBL29744510 | 0.80 | APP (0.67) | MCL1ACMSDTLR8CA12CA1 | |
| SCHEMBL17509379 | 0.79 | ERN1 (0.46) | MCL1ACMSDERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1990011988-A1 | SUBSTITUTED 1-PHENYLNAPHTHALENES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-10-18 | — | — | WO | claimed |
| CN-100354283-C | Covalently fixed non-metallocenes, method for the production thereof and their use for polymerizing olefins | CELANESE VENTURES GMBH (DE) | 2007-12-12 | — | — | CN | disclosed |
| US-7157398-B2 | Covalently fixed nonmetallocenes, process for preparing them and their use for the polymerization of olefins | CELANESE VENTURES GMBH (DE) | 2007-01-02 | — | — | US | disclosed |
| CN-1642962-A | Covalently bound non-metallocenes, method for the production thereof and use thereof in the polymerization of olefins | CELANESE VENTURES GMBH (DE) | 2005-07-20 | — | — | CN | disclosed |
| US-20050148461-A1 | Covalently fixed nonmetallocenes, process for preparing them and their use for the polymerization of olefins | CELANESE VENTURES GMBH (DE) | 2005-07-07 | — | — | US | disclosed |
| US-6872843-B2 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerization of olefins | BASELL POLYOLEFINE GMBH (DE) | 2005-03-29 | — | — | US | disclosed |
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | EQUISTAR CHEMICALS, LP | 2004-02-05 | — | — | US | disclosed |
| WO-1990011988-A1 | SUBSTITUTED 1-PHENYLNAPHTHALENES | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1990-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023940-A1 | Non-metallocene compounds, method for the production thereof and use of the same for the polymerisation of olefins | SOAT2, NOTUM, SOAT1 | MCL1 724/4885ACMSD 955/4885ERN1 2212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.